This is a summary of the European public assessment report (EPAR) for Orgalutran. It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in favour of granting a marketing authorisation and its recommendations on the conditions of use for Orgalutran.
Therapeutic Indication
### Therapeutic indication The prevention of premature luteinising-hormone surges in women undergoing controlled ovarian hyperstimulation for assisted reproduction techniques. In clinical studies, Orgalutran was used with recombinant human follicle-stimulating hormone or corifollitropin alfa, the sustained follicle stimulant.
Therapeutic Area (MeSH)
ATC Code
H01CC01
ATC Item
ganirelix
Pharmacotherapeutic Group
Pituitary and hypothalamic hormones and analogues
Active Substance (Summary)
INN / Common Names
| Substance | CAS | Monograph |
|---|---|---|
| ganirelix | N/A | 加尼瑞克 |
EMA Name
Orgalutran
Medicine Name
Orgalutran
Aliases
N/A
